drugset / Trial / NCT04995835

Cefiderocol PK in Patients on ECMO

NCT04995835

Phase 1 Completed 5 enrolled Joseph L. Kuti, PharmD Shionogi · collab
NaSingle-groupOpen-labelOther

Summary

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving ECMO.

Timeline

Start
2021-07-16
Primary completion
2024-06-01
Completion
2024-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefiderocol Small molecule